One key factor is the rise in healthcare spending in emerging markets. The growing prevalence of chronic diseases, such as diabetes and cancer, is driving the intravenous (IV) therapy and vein access ...
Zacks Investment Research on MSN
Will the FDA's Nod for Subcutaneous Keytruda Ease Merck's Headwinds?
Merck MRK announced that the FDA has approved the subcutaneous (under the skin or SC) formulation of its blockbuster PD-L1 ...
"Intravenous (IV) therapy and vein access play a crucial role in delivering medications, fluids and nutrients directly into the bloodstream. The global market for these technologies is growing due to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback